Clinical Trials Browser

Phase 2 × Cetuximab × 30 days × Clear all

NCT05576896 2026-06-04

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06856213 2026-06-04

ERBIOTAX

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Phase 2 Suspended

Locally Recurrent Skin Squamous Cell Carcinoma

NCT03944941 2026-06-02

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Phase 2 Active not recruiting

60 enrolled 19 charts

Skin Neoplasms

NCT07621497 2026-06-02

FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03691714 2026-06-01

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

35 enrolled 13 charts

Head and Neck Neoplasms, Neoplasm Metastasis

NCT07618624 2026-06-01

BRIDGE

Phase 2 Enrolling by invitation

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03693170 2026-05-29

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT07209111 2026-05-26

KANDLELIT-014

Phase 2 Recruiting

Neoplasms

NCT07252739 2026-05-26

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT03646461 2026-05-22

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Phase 2 Terminated

5 enrolled 9 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03494322 2026-05-20

EACH

Phase 2 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Advanced Colorectal Cancer

NCT06448026 2026-05-20

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2 Recruiting

Mouth Neoplasms

NCT06855212 2026-05-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors